HPS6

Across TCGA pan-cancer cohorts, HPS6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HPS6 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HPS6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HPS6 expression acts as an unfavorable survival marker.

HNSC, LUAD, and THYM are the cancer types where HPS6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.160	0.712	<.001	40	view →
LUAD	DFS	Median	All	0.036	0.768	<.001	15	view →
THYM	DFS	Median	All	0.091	0.884	<.001	12	view →
BLCA	OS	Median	II,III,IV	0.169	0.615	.046	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HPS6–HNSC (DFS)

Open the HNSC breakdown →